Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 7,000 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $50.22, for a total transaction of $351,540.00. Following the completion of the sale, the chief financial officer now directly owns 44,225 shares in the company, valued at approximately $2,220,980. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, May 2nd. They now have a $50.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alkermes Plc from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 16th. They now have a $45.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $49.50.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 1.68% on Friday, hitting $50.94. 1,985,789 shares of the company’s stock traded hands. Alkermes Plc has a 52-week low of $27.72 and a 52-week high of $54.25. The stock has a 50-day moving average of $46.64 and a 200-day moving average of $45.96. The company’s market cap is $7.362 billion.

Alkermes Plc (NASDAQ:ALKS) last released its earnings data on Wednesday, April 30th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the previous year, the company posted $0.40 earnings per share. The company’s revenue for the quarter was down 20.3% on a year-over-year basis. Analysts expect that Alkermes Plc will post $0.49 EPS for the current fiscal year.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.